As 'low­er than pro­ject­ed' da­ta send it back to the draw­ing board, Sanofi takes $1.6B hit on IL-2

One of the key pro­grams that in­spired Sanofi’s $2.5 bil­lion buy­out of Syn­thorx in late 2019 is now the sub­ject of a $1.6 bil­lion write­down.

Sanofi dis­closed in its Q3 earn­ings that it’s clos­ing down Phase II plat­form tri­als for SAR444245, an IL-2 can­di­date that it had hoped would serve as a next-gen foun­da­tion of the on­col­o­gy fran­chise. An ear­ly look at the da­ta, it said, sug­gests ef­fi­ca­cy that’s “low­er than pro­ject­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER